IMUNON Announces Reverse Stock Split

Core Viewpoint - IMUNON, Inc. is implementing a reverse stock split at a ratio of 1-for-15 to meet Nasdaq's minimum bid price requirement for continued listing, effective July 25, 2025 [1][2]. Company Overview - IMUNON is a clinical-stage biotechnology company focused on developing innovative treatments using non-viral DNA technology for various human diseases [5]. - The company's lead clinical program, IMNN-001, is a DNA-based immunotherapy targeting advanced ovarian cancer, which has completed multiple clinical trials [6]. Reverse Stock Split Details - The reverse stock split will reduce the number of outstanding shares from approximately 31.8 million to about 2.1 million shares, with no fractional shares issued [3]. - Stockholders will not need to take action for the exchange of their shares if held in brokerage accounts [4].